Rucaparib, also known as Rubraca, is a PARP inhibitor used to treat BRCA mutation-associated recurrent ovarian lesions and metastatic castration-resistant prostate lesions. It inhibits the activity of PARP enzyme and prevents DNA repair in diseased cells, thereby inducing the death of diseased cells.

The efficacy of Rucaparib

Rucaparib is a PARP inhibitor primarily used for the treatment of BRCA mutation-associated recurrent ovarian lesions and metastatic castration-resistant prostatic lesions. It inhibits the activity of PARP enzyme and prevents DNA repair of diseased cells, thereby inducing the death of diseased cells and prolonging the progression-free survival of patients.

Rucaparib's mechanism of action

Rucaparib prevents diseased cells from repairing DNA damage by inhibiting the activity of PARP1, PARP2, and PARP3 enzymes. BRCA-mutated cells already have DNA repair defects, and Rucaparib further inhibits their repair ability, resulting in the death of diseased cells. This mechanism of action makes it effective in the treatment of BRCA mutation-related lesions.

Indications for Rucaparib

Rucaparib is indicated for the maintenance treatment of BRCA mutation-associated recurrent ovarian lesions, as well as for BRCA-mutated metastatic castration-resistant prostatic lesions. It helps patients manage disease progression and improve quality of life by prolonging progression-free survival.

The efficacy of Rucaparib is significant, but patients need to be aware of its possible side effects and related management measures when using it, and we will introduce the side effects of Rucaparib.

Rucaparib side effects

Patients should regularly monitor blood routine and liver function during medication to prevent possible serious adverse reactions.

Common side effects

Common side effects of Rucaparib include nausea, fatigue, anemia, vomiting, diarrhea, decreased appetite, and thrombocytopenia. Patients should regularly monitor their blood routine and liver function during the medication period, and adjust the dose or suspend the medication according to the doctor's recommendation if necessary.

Management of serious side effects

Rucaparib may cause myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Patients should have regular blood count monitoring during the medication period, and should seek medical attention if abnormal blood counts or related symptoms occur. Your doctor may adjust the dose or pause the medication until your blood counts return to normal.

The side effects of Rucaparib need to be closely monitored, and patients should follow their doctor's instructions when using it, and have regular check-ups, and we will introduce the precautions for using Rucaparib.

Precautions with Rucaparib

The use of Rucaparib requires special attention to myelosuppression, embryo-fetal toxicity, and drug interactions. Patients should regularly monitor blood routine, liver function, and renal function during the medication period to prevent possible serious adverse reactions.

Monitoring for bone marrow suppression

Rucaparib may cause bone marrow suppression, and patients should have their blood count monitored regularly during the medication. If you have anemia, thrombocytopenia or neutropenia, your doctor may adjust the dose or stop taking the medication until your blood counts return to normal.

Prevention of embryo-fetal toxicity

Rucaparib is embryo-fetal toxic and contraindicated in pregnant women. Women of reproductive potential should use effective contraception during the drug and for 6 months after the last dose. Male patients should use effective contraception during the drug and for 3 months after the last dose.

Rucaparib is a prescription drug, and patients should strictly follow the doctor's instructions when using it and have regular check-ups to prevent possible serious adverse reactions.